Article
Biochemistry & Molecular Biology
Su Xian, Magalie Dosset, Gonzalo Almanza, Stephen Searles, Paras Sahani, T. Cameron Waller, Kristen Jepsen, Hannah Carter, Maurizio Zanetti
Summary: Aneuploidy is associated with poor prognosis in cancer types, and the unfolded protein response (UPR) is proposed as a mechanistic link between aneuploidy and immune dysregulation in the tumor microenvironment, showing increased activity of multiple UPR branches in response to aneuploidy.
Review
Medicine, Research & Experimental
Feyza Gul Ozbay Kurt, Samantha Lasser, Ihor Arkhypov, Jochen Utikal, Viktor Umansky
Summary: Despite the success of immune checkpoint inhibitors in melanoma treatment, resistance to them remains a challenge. Myeloid-derived suppressor cells play a crucial role in ICI resistance and creating an immunosuppressive tumor microenvironment. Targeting MDSCs is considered a promising strategy to improve melanoma immunotherapy, and this review discusses the mechanism, studies, and potential strategies for inhibiting MDSC functions.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Biochemistry & Molecular Biology
Mohammad Khoonkari, Dong Liang, Marina Trombetta Lima, Tjitze van der Land, Yuanke Liang, Jianwu Sun, Amalia Dolga, Marleen Kamperman, Patrick van Rijn, Frank A. E. Kruyt
Summary: Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults, and ECM stiffening plays a significant role in its progression. This study identifies a novel mechano-adaptive mechanism involving PERK/FLNA/F-Actin and provides new insights into the cellular adaptation to ECM stiffening.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Amin Izadpanah, Kurtis Willingham, Bysani Chandrasekar, Eckhard U. Alt, Reza Izadpanah
Summary: Cellular stress caused by unfolded protein accumulation is common in rapidly proliferating cancer cells. This stress activates the unfolded protein response (UPR), a set of signal transduction pathways that alleviate the proteostatic stress. The UPR is involved in cancer cell survival and proliferation by upregulating pro-tumorigenic pathways that promote malignant metabolism and neoangiogenesis.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Article
Immunology
Paola Grazioli, Andrea Orlando, Nike Giordano, Claudia Noce, Giovanna Peruzzi, Behnaz Abdollahzadeh, Isabella Screpanti, Antonio Francesco Campese
Summary: This study reveals that dysregulation of the Notch signaling pathway in T cells promotes the production of MDSCs in a T-ALL mouse model. IL-6 is found to mediate the induction of MDSCs in both mouse and human models.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, Research & Experimental
Anik Pramanik, Sankar Bhattacharyya
Summary: The MDSC population in the tumor microenvironment plays a crucial role in tumor immune evasion and cancer progression by disrupting antitumor T cell activity and potentially affecting other immune cell functions.
Article
Immunology
Ambily Anna Mathew, Zahara T. Zakkariya, Anusha Ashokan, Maneesh Manohar, Pavithran Keechilat, Shantikumar V. Nair, Manzoor Koyakutty
Summary: The researchers used various strategies to reverse the non-immunogenic character of the cold tumor, including photodynamic therapy, TAM repolarization, immune checkpoint inhibition, and MDSC depletion. Among them, low-dose 5-fluorouracil chemotherapy showed significant anti-tumor effects, primarily due to the increased infiltration of CD8+ cytotoxic T-cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Weichuan Luo, John V. Napoleon, Fenghua Zhang, Yong Gu Lee, Bingbing Wang, Karson S. Putt, Philip S. Low
Summary: CAR T cell therapies have shown great effectiveness in treating hematopoietic cancers, but their success in solid tumors has been limited. This study investigates the role of immunosuppressive tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in CAR T cell therapy and proposes a method to enhance their efficacy by reprogramming these myeloid cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Alberto Mantovani, Federica Marchesi, Sebastien Jaillon, Cecilia Garlanda, Paola Allavena
Summary: Myeloid cells in tumor tissues, including tumor-associated macrophages and tumor-associated neutrophils, play crucial roles in tumor growth and invasion. In recent years, successful therapeutic approaches have been developed and tested in preclinical cancer models, with some strategies reaching clinical trials.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Review
Immunology
Virginia Camacho, Valeriya Kuznetsova, Robert S. Welner
Summary: The immune microenvironment plays a crucial role in regulating hematopoiesis and immune cell dysfunction significantly contributes to neoplastic disease. Leukemic inflammatory cytokines can alter immune cells, and targeting the immune landscape may have therapeutic value in limiting leukemia growth. Further research is needed to understand how leukemic cytokines impact immune cells and potential immunotherapeutic approaches for patients with hematological myeloid malignancies.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Lifei Liang, Xiaoqing Xu, Jiawei Li, Cheng Yang
Summary: This review summarizes and discusses the bidirectional regulation between miRNAs and MDSCs in the tumor microenvironment, revealing the impact of miRNAs and MDSCs on tumor immune escape and metastasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Filippo Veglia, Emilio Sanseviero, Dmitry I. Gabrilovich
Summary: MDSCs are pathologically activated cells with potent immunosuppressive activity, closely associated with poor clinical outcomes in diseases like cancer. Recent studies have identified key distinctions between MDSCs and classical neutrophils and monocytes, providing new insights into therapeutic targeting for cancer and autoimmune diseases through understanding their genomic and metabolic characteristics. Emerging data also suggest potential involvement of MDSCs in pregnancy, neonatal biology, and COVID-19.
NATURE REVIEWS IMMUNOLOGY
(2021)
Review
Cell Biology
Vaishali Bhardwaj, Stephen M. M. Ansell
Summary: Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells composed of pathologically activated neutrophils and monocytes that negatively regulate the immune response to cancer and chronic infections. They exhibit distinct characteristics and exert strong immunosuppressive effects on T-cells and other immune cells, making them a major obstacle to cancer immunotherapies. However, the clinical outcomes of targeting MDSCs in hematological malignancies, particularly B-cell malignancies, still require further exploration. This review provides a comprehensive summary of the complex biology and immunosuppressive pathways of MDSCs, with a focus on their role in modulating T-cell function in hematological malignancies, and discusses the challenges, therapeutic strategies, and clinical relevance of targeting MDSCs in these diseases.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Pharmacology & Pharmacy
Shweta Joshi, Andrew Sharabi
Summary: This review discusses the role of MDSCs in tumor growth, their interaction with NK cells, and the impact on NK cell-based immunotherapies, presenting strategies to enhance NK cell cytotoxicity.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Ihor Arkhypov, Feyza Gul Ozbay Kurt, Rebekka Bitsch, Daniel Novak, Vera Petrova, Samantha Lasser, Thomas Hielscher, Christopher Groth, Alisa Lepper, Xiaoying Hu, Wei Li, Jochen Utikal, Peter Altevogt, Viktor Umansky
Summary: Soluble HSP90 alpha can convert monocytes into MDSC, which inhibits the antitumor function of T and NK cells. Higher levels of HSP90 alpha in plasma of patients with melanoma are associated with increased PD-L1 expression on MDSC and shorter PFS after ICI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.